Bridgebio Pharma Stock Price, News & Analysis

BridgeBio (Nasdaq: BBIO) will present ten moderated digital posters at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The posters report clinical findings from the ATTRibute-CM study, including data on acoramidis showing reductions in all-cause mortality and cardiovascular hospitalizations, benefits across pre-specified subgroups, effects in the p.V142I (V122I) variant population, and NT-proBNP and quality-of-life improvements.

Presentations are scheduled Nov 8–10 with lead presenters from major centers (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington, and others). A separate poster covers vutrisiran real-world healthcare resource use and mortality from a retrospective database analysis.

BridgeBio (Nasdaq: BBIO) reported Q3 2025 revenue of $120.7M, driven by $108.1M in U.S. Attruby net product sales. As of Oct 25, 2025, 5,259 prescriptions from 1,355 prescribers were written since FDA approval in Nov 2024. The company ended the quarter with $645.9M in cash, cash equivalents and marketable securities.

Clinical highlights include positive topline FORTIFY results for BBP-418 (glycosylated αDG increased 1.8x at 3 months; serum CK reduced 82%; ambulation and FVC improvements) and positive CALIBRATE results for encaleret (76% of participants achieved serum and urine calcium targets at Week 24 vs 4% on conventional therapy). BridgeBio plans NDAs for BBP-418 and encaleret in 1H 2026.

BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 results from CALIBRATE for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The trial met its primary and key secondary endpoints with 76% of encaleret-treated participants reaching target serum and urine calcium at Week 24 versus 4% on conventional therapy (p<0.0001), and 91% achieving intact PTH above the lower reference limit versus 7% on conventional therapy (p<0.0001).

Additional readouts: mean corrected calcium increase of 0.82 mg/dL, mean 24-hour urine calcium reduction of 200 mg/day, 98% in target serum calcium at Week 20, and no discontinuations due to study drug. An NDA submission is planned in H1 2026; pediatric and chronic hypoparathyroidism registrational studies are planned in 2026.

BridgeBio (Nasdaq: BBIO) will release topline results from the ADH1 CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Management will discuss the data on a conference call at 8:00 a.m. ET the same day.

Investors can access a live webcast via the company’s Investors > Events and Presentations page and a replay will be available on the BridgeBio website for 90 days after the event.

BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 FORTIFY results for oral small molecule BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on Oct 27, 2025. Key clinical and biomarker readouts at the planned 12-month interim analysis met endpoints with a favorable safety profile.

Highlights include a 1.8x increase in glycosylated αDG (~17% of control, p<0.0001) sustained to 12 months, an 82% reduction in serum CK (p<0.0001), ambulatory improvement of +0.14 m/s from baseline and +0.27 m/s vs placebo (p<0.0001), and pulmonary benefit of ~+3% predicted FVC from baseline and ~+5% vs placebo (p=0.0071). The company intends to file an NDA with the FDA in H1 2026.

BridgeBio (Nasdaq: BBIO) announced two investor events next week: a webinar to share topline Phase 3 interim results from the LGMD2I/R9 FORTIFY study on Monday, October 27, 2025 at 8:00 AM ET, and its Q3 2025 earnings call on Wednesday, October 29, 2025 at 4:30 PM ET. Management will host both business update calls and provide webcasts accessible via the company’s Investors > Events and Presentations page.

A replay of each webcast will be available on the BridgeBio investor website for 90 days following the events.

BridgeBio Pharma (Nasdaq: BBIO) announced that on October 2, 2025 its compensation committee approved inducement RSU grants to 11 new employees totaling 23,884 shares of common stock under the Amended and Restated 2019 Inducement Equity Plan.

Vesting: 25% of each award vests on November 16, 2026, then 1/12 of the remaining shares vest quarterly thereafter, contingent on continued employment. All awards were granted as inducements pursuant to Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted November 2019 and amended on Feb 10, 2023 and Dec 13, 2023.

BridgeBio Pharma (Nasdaq: BBIO) presented groundbreaking data from the ATTRibute-CM study showing that acoramidis, their oral TTR stabilizer, demonstrates rapid efficacy in treating ATTR-CM (transthyretin amyloid cardiomyopathy). The drug showed significant cardiovascular benefits within the first month of treatment.

Key findings include a 49% hazard reduction in cardiovascular mortality or recurrent hospitalizations through Month 30 (p<0.0001), with 53 events avoided per 100 treated participants. At Month 42, continuous acoramidis treatment reduced cardiovascular mortality by 45% compared to placebo-to-acoramidis switch (p=0.0011).

Acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, Japan, and the UK, has received regulatory approval with labels specifying near-complete TTR stabilization.

BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming participation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 in Minneapolis from September 26-29. The company will present new data about Acoramidis for ATTR-CM treatment through five scientific presentations, including a late-breaking clinical trials session.

The presentations will cover various aspects of Acoramidis treatment, including its effects on cardiovascular outcomes, mortality rates, NT-proBNP levels, and cardiac conduction abnormalities in patients with transthyretin amyloid cardiomyopathy. Distinguished researchers from leading institutions will present the findings across oral and poster sessions.